Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury

(2017) Monicah A Otieno et al.   TOXICOLOGICAL SCIENCES

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

(2016) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

(2015) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Methodology to Assess Clinical Liver Safety Data

(2014) Michael Merz et al.   DRUG SAFETY

How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval

(2013) Arie Regev   Clinics in Liver Disease

A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes

(2012) E Leifke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

(2012) K. Kaku et al.   DIABETES CARE

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

(2012) Charles F Burant et al.   LANCET

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

(2011) G P Aithal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes

(2011) T. Araki et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers

(2011) Himanshu Naik et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method

(2010) Don C. Rockey et al.   HEPATOLOGY

Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion

(2008) S. Edfalk et al.   DIABETES